Literature-reported formulation composition
Component: Lipid 29 | mol%: Not reported | Role: Ionizable lipid
sales@dcchemicals.com
Moderna Lipid 29
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Literature-reported formulation composition
Component: Structural phospholipid | mol%: Not reported | Role: structural_lipid
Literature-reported formulation composition
Component: Phospholipid (if used) | mol%: Not reported | Role: Helper phospholipid
Literature-reported formulation composition
Component: PEG-lipid | mol%: Not reported | Role: PEG lipid
Literature-reported formulation composition
Component: Reported total | mol%: Not reported | Role: Source values retained
Table 2
Experiment: Mouse hEPO mRNA | Condition: 0.5 mg/kg IV bolus, CD-1 mice, n=5 | Lipid 29 result: Highest expression among the tested tail/headgroup series; lead selected
Table 2
Experiment: Mouse luciferase mRNA | Condition: Whole-body bioluminescence comparison | Lipid 29 result: More than 20-fold greater AUEC than lipid 1 LNPs
Table 2
Experiment: Cynomolgus hEPO mRNA | Condition: 0.1 mg/kg, 60-min IV infusion, n=6 | Lipid 29 result: Approximately 2-fold higher Emax and >6-fold higher AUEClast than lipid 1
Table 2
Experiment: LNP structure | Condition: Cryo-EM/SAXS | Lipid 29 result: Lipid 29 showed more organized multilamellar features; d-spacing 4.76 nm vs 6.56 nm for lipid 1
Reported observation
Literature-reported Mouse hEPO mRNA expression Highest expression among tested series 0.5 mg/kg IV bolus, CD-1 mice, n=5 · Lipid 1 and analog series Article Fig. 1b and section 2.1
Reported observation
Literature-reported Mouse luciferase mRNA AUEC >20-fold versus lipid 1 Whole-body bioluminescence · Lipid 1 LNP Article Fig. S4 and section 2.1
Reported observation
Literature-reported Cynomolgus hEPO Emax 2-fold higher 0.1 mg/kg, 60-min IV infusion, n=6 · Lipid 1 LNP Article Fig. 3
Reported observation
Literature-reported Cynomolgus hEPO AUEClast >6-fold higher 0.1 mg/kg, 60-min IV infusion, n=6 · Lipid 1 LNP Article Fig. 3
Reported observation
PEG-lipid sensitivity Lipid 29 maintained consistent particle size and low PDI across 0-3 mol% PEG-lipid, including 0 mol%; long-term stability at very low PEG was not determined. · Article section 2.3, Fig. 6.
Reported observation
Proposed lipid–mRNA interactions Molecular-dynamics simulations indicated squaramide 29 hydrogen-bond and pi-stacking interactions with exposed RNA nucleobases/sugars; this is a mechanistic hypothesis from simulations, not a standalone efficacy guarantee. · Article section 2.2, Fig. 4.